|
FDA Sets Early February PDUFA Date for Ampligen
The FDA has set a Feb. 2, 2013, action goal date for Hemispherx Biopharma’s Ampligen, signaling an end to the rocky review of the chronic fatigue syndrome (CFS) drug.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives